Big U.S. pharmacies square off on Daraprim supplies
(Reuters) - As Turing Pharmaceuticals Chief Executive Officer Martin Shkreli contends with charges of securities fraud, major U.S. pharmacies are moving to assure patients of continued access to the company's key drug, Daraprim.
Aucun commentaire:
Enregistrer un commentaire